MCID: SLV012
MIFTS: 50

Salivary Gland Adenoid Cystic Carcinoma malady

Categories: Rare diseases, Cancer diseases, Oral diseases, Skin diseases, Endocrine diseases

Aliases & Classifications for Salivary Gland Adenoid Cystic Carcinoma

About this section

Aliases & Descriptions for Salivary Gland Adenoid Cystic Carcinoma:

Name: Salivary Gland Adenoid Cystic Carcinoma 11 50 13
Adenoid Cystic Carcinoma 11 48 68
Cylindroma 11 48
Adenoid Cystic Carcinoma of Salivary Gland 68
Carcinoma, Adenoid Cystic 39
Eccrine Dermal Cylindroma 68
 
Carcinoma Adenoid Cystic 50
Adenoid Cystic Cancer 11
Adenocystic Carcinoma 48
Carcinoma, Cribriform 68
Cribriform Carcinoma 48
Cylindroma Nos 11

Classifications:



External Ids:

Disease Ontology11 DOID:4866
MeSH39 D003528
NCIt45 C2970

Summaries for Salivary Gland Adenoid Cystic Carcinoma

About this section
NIH Rare Diseases:48 Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma, which is cancer that begins in gladular tissues. ACC most commonly arises in the head and neck, in various parts of the major and minor salivary glands including the palate, nasopharynx, lining of the mouth, voice box (larynx) or windpipe (trachea). It can also occur in the breast, uterus, or other locations in the body. Early symptoms depend on the tumor's location and may include lumps under the lining of the mouth or facial skin; numbness in the mouth or face; difficulty swallowing; hoarseness; pain; or paralysis of a facial nerve. ACC often has long periods with no growth followed by growth spurts; however, it can be aggressive in some people. ACC spreads along nerves or through the bloodstream, and only spreads to the lymph nodes in about 5-10% of cases. The cause of ACC is currently unknown. Treatment depends on many factors and may include surgery, radiation, and/or chemotherapy. Last updated: 12/10/2014

MalaCards based summary: Salivary Gland Adenoid Cystic Carcinoma, also known as adenoid cystic carcinoma, is related to prostate adenoid cystic carcinoma and cervical adenoid cystic carcinoma, and has symptoms including pain and pain. An important gene associated with Salivary Gland Adenoid Cystic Carcinoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways are GADD45 Pathway and Thyroid cancer. Affiliated tissues include salivary gland, lung and brain, and related mouse phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and neoplasm.

Disease Ontology:11 A salivary gland carcinoma that is characterized by a distinctive pattern in which abnormal nests or cords of epithelial cells surround and/or infiltrate ducts or glandular structures within the affected organ. These structures are typically filled with a mucous-like material or contain abnormal fibrous membranes.

Wikipedia:71 Adenoid cystic carcinoma (sometimes referred to as adenocyst, malignant cylindroma, adenocystic,... more...

Related Diseases for Salivary Gland Adenoid Cystic Carcinoma

About this section

Diseases related to Salivary Gland Adenoid Cystic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 75)
idRelated DiseaseScoreTop Affiliating Genes
1prostate adenoid cystic carcinoma29.7AQP1, CCND1, CTTN, CYLD, EN1, KIT
2cervical adenoid cystic carcinoma12.3
3maxillary sinus adenoid cystic carcinoma12.3
4lacrimal gland adenoid cystic carcinoma12.3
5esophageal adenoid cystic carcinoma12.2
6laryngeal adenoid cystic carcinoma12.2
7breast adenoid cystic carcinoma12.2
8bartholin's gland adenoid cystic carcinoma12.2
9cribriform carcinoma12.1
10lung adenoid cystic carcinoma12.1
11trachea adenoid cystic carcinoma12.1
12ethmoid sinus adenoid cystic carcinoma12.1
13parotid gland adenoid cystic carcinoma12.0
14adenoid cystic carcinoma of the corpus uteri12.0
15sublingual gland adenoid cystic carcinoma12.0
16malignant cylindroma12.0
17cutaneous adenocystic carcinoma12.0
18brooke-spiegler syndrome11.9
19adnexal spiradenoma/cylindroma of a sweat gland11.8
20poncet-spiegler's cylindroma11.8
21cylindromatosis, familial11.8
22lymph node adenoid cystic carcinoma11.0
23adenoiditis10.9
24pachyonychia congenita 310.8
25pachyonychia congenita 410.8
26pachyonychia congenita 110.8
27pachyonychia congenita 210.8
28ceruminous carcinoma10.8
29lysosomal storage disease10.5BCL2, CCND1
30solitary osseous plasmacytoma10.5BCL2, CCND1
31hepatic osteogenic sarcoma10.4AQP1, BCL2
32peripheral nervous system disease10.4KIT, NOS2
33malignant biphasic mesothelioma10.4KIT, PCNA
34urethra squamous cell carcinoma10.4CDH1, RUNX3
35mucinous stomach adenocarcinoma10.3MKI67, PCNA
36focal chorioretinitis10.3KIT, MKI67
37spiradenoma10.3
38pura syndrome10.3KIT, MKI67
39pylorus cancer10.3BCL2, PCNA
40multidrug-resistant tuberculosis10.2CCND1, KIT, PCNA
41myopathy10.2CCND1, KIT, PCNA
42gynecomastia10.2AQP1, PCNA
43polyomavirus allograft nephropathy10.2CCND1, KIT, MKI67
44eversion of lacrimal punctum10.2CCND1, CTTN
45stampe sorensen syndrome10.2BCL2, MKI67
46tic disorder10.2CCND1, CTTN
47novak syndrome10.2BCL2, CCND1, MKI67
48mixed extragonadal germ cell cancer10.2CCND1, KIT, MKI67
49gastric fundus cancer10.2CCND1, CDH1, RUNX3
50x-linked congenital generalized hypertrichosis10.2BCL2, MKI67

Graphical network of the top 20 diseases related to Salivary Gland Adenoid Cystic Carcinoma:



Diseases related to salivary gland adenoid cystic carcinoma

Symptoms & Phenotypes for Salivary Gland Adenoid Cystic Carcinoma

About this section

UMLS symptoms related to Salivary Gland Adenoid Cystic Carcinoma:


pain

GenomeRNAi Phenotypes related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00104-A-09.9CCND1, MKI67, PCNA

MGI Mouse Phenotypes related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

41 (show all 14)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020067.9BCL2, CCND1, CDH1, CYLD, KIT, NOS2
2MP:00053817.8BCL2, CCND1, CDH1, CYLD, KIT, NOS2
3MP:00107717.6BCL2, CCND1, CDH1, CYLD, EN1, KIT
4MP:00053887.5AQP1, BCL2, CCND1, CTTN, CYLD, KIT
5MP:00053867.2AQP1, BCL2, CCND1, CYLD, EN1, KIT
6MP:00053847.1BCL2, CCND1, CDH1, CTTN, CYLD, EN1
7MP:00053896.8AQP1, BCL2, CCND1, CDH1, CTTN, EN1
8MP:00053796.7AQP1, BCL2, CCND1, CDH1, CYLD, EN1
9MP:00053876.7BCL2, CCND1, CDH1, CTTN, CYLD, EN1
10MP:00053766.6AQP1, BCL2, CCND1, CDH1, CYLD, EN1
11MP:00053856.5AQP1, BCL2, CCND1, CDH1, CTTN, EN1
12MP:00053976.4AQP1, BCL2, CCND1, CTTN, CYLD, EN1
13MP:00053785.9AQP1, BCL2, CCND1, CDH1, CTTN, CYLD
14MP:00107685.5AQP1, BCL2, CCND1, CDH1, CTTN, CYLD

Drugs & Therapeutics for Salivary Gland Adenoid Cystic Carcinoma

About this section

Drugs for Salivary Gland Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 163)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
FluconazoleapprovedPhase 2, Phase 317886386-73-43365
Synonyms:
2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL
2-(2,4-DIFLUOROPHENYL)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol
2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
86386-73-4
AC-428
AC1L1FRQ
AC1Q77FV
AKOS000280854
AbZ Brand of Fluconazole
Afungil
Alflucoz
Aliud Brand of Fluconazole
Alpharma Brand of Fluconazole
Apo Fluconazole
Apo-Fluconazole
Apotex Brand of Fluconazole
Armstrong Brand of Fluconazole
BIDD:GT0799
BRD-K05977355-001-02-6
BSPBio_003504
Baten
Beagyne
Bio-0041
Biocanol
Biozole
Biozolene
C13H12F2N6O
CCRIS 7211
CHEBI:46081
CHEMBL106
CID3365
CPD000471882
Canzol
Chemia Brand of Fluconazole
Cryptal
D00322
D015725
DB00196
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
DIFLUCAN IN SODIUM CHLORIDE 0.9%
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
DRG-0005
Diflazon
Diflucan
Diflucan (TN)
Diflucan, Trican, Alfumet, Fluconazole
Dimycon
DivK1c_001030
Effik Brand of Fluconazole
Elazor
F0677
F8929_SIGMA
FCZ
FLCZ
Fluc Hexal
Flucazol
FlucoLich
Flucobeta
Fluconazol
Fluconazol AL
Fluconazol AbZ
Fluconazol Isis
Fluconazol Stada
Fluconazol [Spanish]
Fluconazol ratiopharm
Fluconazol von ct
Fluconazol-Isis
Fluconazol-ratiopharm
Fluconazole & Bovine Lactoferrin
Fluconazole & Human recombinant granulocyte colony stimulating factor
Fluconazole & MC-510,011
Fluconazole & hGCSF
Fluconazole (JAN/USAN/INN)
Fluconazole [USAN:INN:BAN:JAN]
Fluconazole in combination with MGCD290
Fluconazole in dextrose 5% in plastic container
Fluconazole in sodium chloride 0.9%
Fluconazole in sodium chloride 0.9% in plastic container
Fluconazolum
Fluconazolum [Latin]
Flucostat
 
Flucytosine & Nyotran
Flucytosine & Nyotran(Liposomal Nystatin)
Flukezol
Flunazul
Flunizol
Fluzone
Forcan
Fuconal
Fungata
GL663142 & Fluconazole
HMS1922O10
HMS2090I20
HMS2093M21
HMS503M21
HSDB 7420
Hexal Brand of Fluconazole
I06-0069
IDI1_001030
KBio1_001030
KBio2_002134
KBio2_004702
KBio2_007270
KBio3_003009
KBioGR_000360
KBioSS_002134
KS-1059
LS-1858
Lavisa
Lesvi Brand of Fluconazole
Lichtenstein Brand of Fluconazole
Loitin
MLS001066394
MLS001165780
MLS001195645
MLS001304713
MLS001306492
Mack Brand of Fluconazole
MolPort-000-883-859
MolPort-002-885-825
Mutum
NCGC00095089-01
NCGC00095089-02
NCGC00095089-04
NCGC00095089-05
NINDS_001030
Neofomiral
Oxifugol
Oxifungol
Pfizer Brand of Fluconazole
Pfleger Brand of Fluconazole
Pritenzol
S1331_Selleck
SAM002589905
SAT Brand of Fluconazole
SMR000471882
SPBio_001613
SPECTRUM1503975
STK619301
Silanes Brand of Fluconazole
Solacap
Spectrum2_001607
Spectrum3_001912
Spectrum4_000090
Spectrum5_001277
Spectrum_001654
Stada Brand of Fluconazole
Syscan
TL8005609
TPF
Triflucan
UK 49858
UK-49858
UK49858
UNII-8VZV102JFY
Vita Brand of Fluconazole
XMP.284 & Fluconazole
XMP.366 & Fluconazole
XMP.391 & Fluconazole
ZINC00004009
Zemyc
Zoltec
Zonal
betapharm Brand of Fluconazole
ct Arzneimittel Brand of Fluconazole
ct-Arzneimittel Brand of Fluconazole
fluconazole
nchembio.100-comp3
nchembio.65-comp15
ratiopharm Brand of Fluconazole
2
Miconazoleapproved, investigational, vet_approvedPhase 2, Phase 3, Phase 1362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
3
Fentanylapproved, illicit, investigational, vet_approvedPhase 3773437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
4
CevimelineapprovedPhase 35107233-08-983898, 25137844
Synonyms:
(+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate
(+/-)cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate
(2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride
107233-08-9
153504-70-2
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
AC1L36EF
AC1L36GD
AC1NR4MS
AC1OCEXD
AF 102B
AF-102B
AF102B
BIDD:GT0265
C10H17NOS
CHEMBL1200362
CID5284532
CID6918023
CID83898
CID83927
Cevimelina
Cevimeline
Cevimeline (INN)
Cevimeline HCl 1/2H2O
Cevimeline [INN]
 
Cevimeline hydrochloride
Cevimeline hydrochloride (USAN)
Cevimeline hydrochloride [USAN]
Cevimeline hydrochloride hemihydrate
Cevimeline hydrochloride hydrate
Cevimeline hydrochloride hydrate (JAN)
Cevimeline.HCl
Cevimelinum
D00661
D07667
DB00185
Evoxac
Evoxac (TN)
FKS-508
Fks 508
HSDB 7286
LS-145782
LS-172037
NCGC00181793-01
SND 5008, AF-102B, FKS-508
SND-5008
SNI-2011
SNK-508
Saligren
Saligren (TN)
Sni 2011
UNII-K9V0CDQ56E
UNII-P81Q6V85NP
cevimeline hydrochloride hydrate
cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1)
5
Megestrol acetateapproved, vet_approvedPhase 367595-33-511683
Synonyms:
17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate
17alpha-Acetoxy-6-dehydro-6-methylprogesterone
17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
17α-Acetoxy-6-dehydro-6-methylprogesterone
17α-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
6-Dehydro-6-methyl-17alpha-acetoxyprogesterone
6-Dehydro-6-methyl-17α-acetoxyprogesterone
6-Methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione
 
6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate
6-Methyl-17α-acetoxypregna-4,6-diene-3,20-dione
6-Methyl-17α-hydroxy-delta(sup 6)-progesterone acetate
6-Methyl-6-dehydro-17alpha-acetoxyprogesterone
6-Methyl-6-dehydro-17α-acetoxyprogesterone
6-Methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate
6-Methyl-delta(sup 4,6)-pregnadien-17α-ol-3,20-dione acetate
6-Methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone
6-Methyl-delta(sup 6)-dehydro-17α-acetoxyprogesterone
MGA
Megace
6
Histamine PhosphateapprovedPhase 3103351-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
 
EINECS 200-118-4
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
7
DoxepinapprovedPhase 3131668-19-5667477, 667468
Synonyms:
(3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
(3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
(3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine
(3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
(3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
(Z)-Doxepin
11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine
11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin
11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin
1668-19-5
3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine
3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
3607-18-9
AC1L1FAW
AC1LDI5F
AC1LDI63
AC1NUW4A
AKOS001582771
Adapin
Aponal
BPBio1_000118
BRD-K36616567-003-01-5
BRD-K37694030-003-02-8
BRD-K54462405-003-03-3
BSPBio_000106
BSPBio_001934
C06971
C19H21NO
CAS-1229-29-4
CCRIS 9176
CHEBI:36691
CHEBI:36692
CHEBI:4710
CHEMBL101740
CID10039438
CID3158
CID5462131
CID667468
CID667477
Cidoxepin
Cidoxepin [INN]
Cidoxepina
Cidoxepinum
Curatin
D07875
DB01142
DivK1c_000431
Doxepin
Doxepin (INN)
Doxepin (Z)-isomer
Doxepin Hcl
Doxepin Hydrochloride,
Doxepin [USAN]
 
Doxepin, Hydrochloride
Doxepina
Doxepina [INN-Spanish]
Doxepine
Doxepinum
Doxepinum [INN-Latin]
HSDB 3069
IDI1_000431
KBio1_000431
KBio2_001285
KBio2_003853
KBio2_006421
KBio3_001154
KBioGR_001131
KBioSS_001285
L000699
LS-174582
LS-61638
Lopac-D-4526
Lopac0_000339
MF 10
MOLI001594
MolPort-003-847-024
MolPort-005-933-834
N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine
NCGC00015344-01
NCGC00015344-02
NCGC00015344-04
NCGC00024623-01
NCGC00024623-02
NCGC00162127-01
NINDS_000431
Oprea1_473232
Prestwick0_000263
Prestwick1_000263
Prestwick2_000263
Prestwick3_000263
Quitaxon
SPBio_000206
SPBio_002325
Sinequan
Sinequan (TN)
Spectrum2_000133
Spectrum3_000407
Spectrum4_000526
Spectrum5_001051
Spectrum_000805
Tocris-0508
Triadapin
UNII-5ASJ6HUZ7D
UNII-F96TTB8728
Zonalon
cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin
cis-doxepin
doxepin
8
HistamineapprovedPhase 3103475614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
9
Docetaxelapproved, investigational, Approved May 1996Phase 3, Phase 1, Phase 21918114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
10Cytochrome P-450 Enzyme InhibitorsPhase 2, Phase 33822
11Anti-Infective AgentsPhase 2, Phase 3, Phase 121402
12Liver ExtractsPhase 3, Phase 2, Phase 13868
13Alkylating AgentsPhase 3, Phase 2, Phase 14694
14Steroid Synthesis InhibitorsPhase 2, Phase 31718
15Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 2, Phase 312767
16Autonomic AgentsPhase 39774
17Antineoplastic Agents, HormonalPhase 35407
18Contraceptives, OralPhase 31292
19
MegestrolPhase 3673562-63-819090, 3080587
Synonyms:
(8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione
3562-63-8
AC1L2DG3
C07120
CID19090
Chronopil
Chronopil (TN)
D008535
D08167
DB00351
 
EINECS 222-628-6
HSDB 3233
LS-118488
MGA
Megestrol (INN)
Megestrol Acetate
Megestrol [INN:BAN]
Megestrolo
Megestrolo [DCIT]
Megestrolum [INN-Latin]
Megestryl acetate
UNII-EA6LD1M70M
megestrol
20Antimitotic AgentsPhase 3, Phase 2, Phase 15498
21Contraceptive AgentsPhase 31901
22Appetite StimulantsPhase 364
23Neurotransmitter AgentsPhase 317734
24HormonesPhase 2, Phase 3, Phase 113979
25Cholinergic AgentsPhase 33846
26Central Nervous System StimulantsPhase 32132
27Adjuvants, AnesthesiaPhase 31588
28AnalgesicsPhase 311287
29Analgesics, OpioidPhase 33091
30AnestheticsPhase 39001
31PorfiromycinPhase 34
32Nucleic Acid Synthesis InhibitorsPhase 3, Phase 1, Phase 24855
33Anti-Bacterial AgentsPhase 3, Phase 2, Phase 110884
34Hormone AntagonistsPhase 2, Phase 312778
35MitomycinsPhase 3233
36Anesthetics, GeneralPhase 32787
37Antibiotics, AntitubercularPhase 3, Phase 2, Phase 16972
38Peripheral Nervous System AgentsPhase 322776
39NarcoticsPhase 33486
40Antifungal AgentsPhase 2, Phase 3, Phase 13615
41Cytochrome P-450 CYP2C9 InhibitorsPhase 2, Phase 3658
42Anesthetics, IntravenousPhase 32406
43Central Nervous System DepressantsPhase 312806
44pancreatic polypeptidePhase 3, Phase 120
45Psychotropic DrugsPhase 36279
46Histamine AntagonistsPhase 3946
47Antidepressive AgentsPhase 32666
48Antidepressive Agents, TricyclicPhase 3293
49ColaNutraceuticalPhase 3, Phase 2, Phase 11881
50
IndinavirapprovedPhase 2110150378-17-95362440
Synonyms:
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide
(2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
150378-17-9
157810-81-6
157810-81-6 (sulfate (1:1) (salt))
166746-42-5
1c6y
1hsg
1hsh
1k6c
1sdt
1sdu
1sdv
1sgu
216884-06-9
2avo
2avs
2avv
2bpx
AC-20034
AC1L1U7I
AKOS000280989
BIDD:GT0378
BIDD:PXR0141
C07051
 
C36H47N5O4
CHEBI:44032
Compound J
Crixivan
Crixivan (TM)
DB00224
IDV
Indinavir (*1:1 Sulfate salt*)
Indinavir [USAN]
Indinavir anhydrous
Indinavir sulfate
Indinavir sulphate
Indinavir, Sulfate (1:1)
L 735524
L-735 524
L-735,524
L-735524
LS-173382
MK-639
MolPort-000-883-804
N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE
NCGC00159460-02
NSC697197
Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide
Propolis+Indinavir
RS-253
UNII-9MG78X43ZT
indinavir

Interventional clinical trials:

(show top 50)    (show all 107)
idNameStatusNCT IDPhase
1Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck CancerCompletedNCT00002507Phase 3
2Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
3Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck CancerCompletedNCT00090337Phase 3
4Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck CancerCompletedNCT00002533Phase 2, Phase 3
5Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck CancerCompletedNCT00017511Phase 3
6Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive TractCompletedNCT00765440Phase 3
7Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck CancerCompletedNCT00006799Phase 3
8Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without ChemotherapyActive, not recruitingNCT01156142Phase 3
9Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant TumorsNot yet recruitingNCT02838602Phase 3
10Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By SurgeryWithdrawnNCT00041171Phase 3
11Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and NeckUnknown statusNCT00180921Phase 2
12Antineoplaston Therapy in Treating Patients With Advanced Head and Neck CancerUnknown statusNCT00003489Phase 2
13Trastuzumab in Treating Patients With Advanced Salivary Gland CancerUnknown statusNCT00004163Phase 2
14Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Salivary Gland Cancer That Cannot Be Removed By SurgeryUnknown statusNCT00101075Phase 2
15External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain MetastasesUnknown statusNCT00637637Phase 2
16A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary GlandsCompletedNCT00886132Phase 2
17Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and NeckCompletedNCT00581360Phase 2
18Study of RAD001 in Adenoid Cystic CarcinomaCompletedNCT01152840Phase 2
19Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaCompletedNCT01558661Phase 2
20Dovitinib in Adenoid Cystic CarcinomaCompletedNCT01417143Phase 2
21Study of Dovitinib (TKI258) in Adenoid Cystic CarcinomaCompletedNCT01524692Phase 2
22A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary GlandsCompletedNCT01678105Phase 2
23Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and NeckCompletedNCT00077428Phase 2
24Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and NeckCompletedNCT00017498Phase 2
25Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland CancersCompletedNCT00095563Phase 2
26Imatinib Mesylate in Treating Patients With Salivary Gland CancerCompletedNCT00045669Phase 2
27Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1, Phase 2
28Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerCompletedNCT00492089Phase 2
29High-dose ICE With AmifostineCompletedNCT00003657Phase 2
30Chemotherapy in Treating Patients With Solid TumorsCompletedNCT00003103Phase 1, Phase 2
31Docetaxel in Treating Patients With Solid TumorsCompletedNCT00003565Phase 2
32Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck CancerCompletedNCT00448552Phase 2
33Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth CancerCompletedNCT00004901Phase 1, Phase 2
34Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid TumorsCompletedNCT00019331Phase 2
35Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid TumorCompletedNCT00021047Phase 1, Phase 2
36Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2
37Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During SurgeryCompletedNCT00003744Phase 2
38Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung CancerCompletedNCT00021333Phase 2
39Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland TumorCompletedNCT00079079Phase 2
40Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck CancerCompletedNCT00509665Phase 2
41Iressa Study in Patients With Salivary Gland CancerCompletedNCT00509002Phase 2
42Testing Lenvatinib in Patients With Adenoid Cystic CarcinomaRecruitingNCT02780310Phase 2
43A Study of Apatinib in Metastatic Adenoid Cystic Carcinoma of the Head and NeckRecruitingNCT02775370Phase 2
44Adenoid Cystic Carcinoma, Erbitux, and Particle TherapyRecruitingNCT01192087Phase 1, Phase 2
45Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14RecruitingNCT02860936Phase 2
46Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic CarcinomaRecruitingNCT02859012Phase 2
47Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14RecruitingNCT02857712Phase 2
48Intensity-Modulated or Proton Radiation Therapy for Sinonasal MalignancyRecruitingNCT01586767Phase 2
4918F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyRecruitingNCT01806675Phase 1, Phase 2
50Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaActive, not recruitingNCT02098538Phase 2

Search NIH Clinical Center for Salivary Gland Adenoid Cystic Carcinoma


Cochrane evidence based reviews: carcinoma, adenoid cystic

Genetic Tests for Salivary Gland Adenoid Cystic Carcinoma

About this section

Anatomical Context for Salivary Gland Adenoid Cystic Carcinoma

About this section

MalaCards organs/tissues related to Salivary Gland Adenoid Cystic Carcinoma:

36
Salivary gland, Lung, Brain, Trachea, Skin, Liver, Kidney

Publications for Salivary Gland Adenoid Cystic Carcinoma

About this section

Articles related to Salivary Gland Adenoid Cystic Carcinoma:

(show top 50)    (show all 58)
idTitleAuthorsYear
1
Type III TGF-I^ receptor inhibits cell proliferation and migration in salivary glands adenoid cystic carcinoma by suppressing NF-I_B signaling. (26531330)
2016
2
Carcinoma-Associated Fibroblasts Lead the Invasion of Salivary Gland Adenoid Cystic Carcinoma Cells by Creating an Invasive Track. (26954362)
2016
3
Identification of methylated genes in salivary gland adenoid cystic carcinoma xenografts using global demethylation and methylation microarray screening. (27212063)
2016
4
Inhibitory effects of silibinin on proliferation and lung metastasis of human high metastasis cell line of salivary gland adenoid cystic carcinoma via autophagy induction. (27822066)
2016
5
Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. (26862087)
2016
6
Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but Not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study. (27000157)
2016
7
Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma. (26631070)
2016
8
PAK2 promotes migration and proliferation of salivary gland adenoid cystic carcinoma. (27648129)
2016
9
Downregulation of nucleophosmin expression inhibited proliferation and induced apoptosis in salivary gland adenoid cystic carcinoma. (27501253)
2016
10
Salivary gland adenoid cystic carcinoma. (26214665)
2015
11
Role of hypoxia-inducible factor-1I+ and CD146 in epidermal growth factor receptor-mediated angiogenesis in salivary gland adenoid cystic carcinoma. (25997612)
2015
12
Inhibition of STAT3 reduces proliferation and invasion in salivary gland adenoid cystic carcinoma. (26175943)
2015
13
MicroRNA-101-3p suppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim-1. (26693056)
2015
14
Aberrant Wnt-1/beta-catenin signaling and WIF-1 deficiency are important events which promote tumor cell invasion and metastasis in salivary gland adenoid cystic carcinoma. (26405993)
2015
15
Inhibition of mTOR reduce Stat3 and PAI related angiogenesis in salivary gland adenoid cystic carcinoma. (25520866)
2014
16
Pim-1 acts as an oncogene in human salivary gland adenoid cystic carcinoma. (25551195)
2014
17
A study on the inhibition of VEGF expression in salivary gland adenoid cystic carcinoma cells via iNOS gene RNAi in vitro. (25065562)
2014
18
Aquaporin-1 promoter hypermethylation is associated with improved prognosis in salivary gland adenoid cystic carcinoma. (24493792)
2014
19
High expression of SOX2 is associated with poor prognosis in patients with salivary gland adenoid cystic carcinoma. (24828201)
2014
20
Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic carcinoma. (24510998)
2014
21
19-year oncologic outcomes and the benefit of elective neck dissection in salivary gland adenoid cystic carcinoma. (24170702)
2013
22
Expression of podoplanin in salivary gland adenoid cystic carcinoma and its association with distant metastasis and clinical outcomes. (22580922)
2012
23
Developmental transcription factor EN1--a novel biomarker in human salivary gland adenoid cystic carcinoma. (21800291)
2012
24
Salivary gland adenoid cystic carcinoma with cervical lymph node metastasis: a preliminary study of 62 cases. (22647764)
2012
25
High expression of the autophagy gene Beclin-1 is associated with favorable prognosis for salivary gland adenoid cystic carcinoma. (22712799)
2012
26
Critical regions and spreading of runt-related transcription factor-3 C-phosphate-G (CpG) island methylation in human salivary gland adenoid cystic carcinoma. (21658745)
2011
27
CpG island methylation profiling in human salivary gland adenoid cystic carcinoma. (21692051)
2011
28
Unfavorable clinical implications for hypermethylation of RUNX3 in patients with salivary gland adenoid cystic carcinoma. (21567090)
2011
29
Expression of the membrane-cytoskeletal linker Ezrin in salivary gland adenoid cystic carcinoma. (21550270)
2011
30
Integrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma. (21551254)
2011
31
Metastatic pleural effusion: a rare presentation of salivary gland adenoid cystic carcinoma. (21545072)
2011
32
Maslinic acid induces apoptosis in salivary gland adenoid cystic carcinoma cells by Ca2+-evoked p38 signaling pathway. (21279332)
2011
33
Evolution pattern of the Runx3 gene 5'-CpG island methylation in human salivary gland adenoid cystic carcinoma]. (21223798)
2010
34
RUNX3 expression and its methylation of 5'-CpG island in salivary gland adenoid cystic carcinoma cell lines ACC-2, ACC-3 and ACC-M]. (21223819)
2010
35
RNAi knockdown of C-erbB2 expression inhibits salivary gland adenoid cystic carcinoma SACC-83 cell growth in vitro. (23554633)
2010
36
Sulforaphane induces G2-M arrest and apoptosis in high metastasis cell line of salivary gland adenoid cystic carcinoma. (19589718)
2009
37
Effects of Ezrin gene on the proliferation and invasion activity of human salivary gland adenoid cystic carcinoma]. (19575999)
2009
38
NF-kappaB promotes iNOS and VEGF expression in salivary gland adenoid cystic carcinoma cells and enhances endothelial cell motility in vitro. (19317804)
2009
39
Synergistic inhibitory effect of sulforaphane and 5-fluorouracil in high and low metastasis cell lines of salivary gland adenoid cystic carcinoma. (18844240)
2009
40
Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma. (19688981)
2009
41
Survival from salivary glands adenoid cystic carcinoma in European populations. (19095489)
2009
42
Choroidal metastasis from submandibular salivary gland adenoid cystic carcinoma. (18254353)
2008
43
Tamoxifen for salivary gland adenoid cystic carcinoma: report of two cases. (18347813)
2008
44
Coordinated expression of activated mitogen-activated protein kinases in salivary gland adenoid cystic carcinoma. (18657296)
2008
45
High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. (18326020)
2008
46
Fine-needle aspiration biopsy as an auxiliary diagnostic tool on intraoral minor salivary gland adenoid cystic carcinoma. (18644520)
2008
47
DNA copy number gains at loci of growth factors and their receptors in salivary gland adenoid cystic carcinoma. (17545515)
2007
48
In vitro angiogenesis and expression of nuclear factor kappaB and VEGF in high and low metastasis cell lines of salivary gland Adenoid Cystic Carcinoma. (17543095)
2007
49
SIKVAV, a laminin alpha1-derived peptide, interacts with integrins and increases protease activity of a human salivary gland adenoid cystic carcinoma cell line through the ERK 1/2 signaling pathway. (17591960)
2007
50
Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma. (17520682)
2007

Variations for Salivary Gland Adenoid Cystic Carcinoma

About this section

Cosmic variations for Salivary Gland Adenoid Cystic Carcinoma:

8 (show top 50)    (show all 184)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM34768RPS6KB2salivary gland,NS,carcinoma,adenoid cystic carcinomac.986G>Ap.R329Q25
2COSM33969KITsalivary gland,NS,carcinoma,adenoid cystic carcinomac.1771T>Cp.F591L25
3COSM1658931CACNA1Dsalivary gland,NS,carcinoma,adenoid cystic carcinomac.5255C>Tp.A1752V25
4COSM1659096POLDIP3salivary gland,NS,carcinoma,adenoid cystic carcinomac.1083C>Tp.I361I25
5COSM1659115BCORL1salivary gland,NS,carcinoma,adenoid cystic carcinomac.4854G>Cp.G1618G25
6COSM33968KITsalivary gland,NS,carcinoma,adenoid cystic carcinomac.1685A>Tp.E562V25
7COSM1658892HK1salivary gland,NS,carcinoma,adenoid cystic carcinomac.370C>Gp.H124D25
8COSM1658879PORCNsalivary gland,NS,carcinoma,adenoid cystic carcinomac.1073C>Ap.T358N25
9COSM1658998SF3B1salivary gland,NS,carcinoma,adenoid cystic carcinomac.1873C>Ap.R625S25
10COSM1658865UNC80salivary gland,NS,carcinoma,adenoid cystic carcinomac.305A>Gp.Q102R25
11COSM1658881ADCYAP1salivary gland,NS,carcinoma,adenoid cystic carcinomac.295C>Ap.L99M25
12COSM1658965DYRK4salivary gland,NS,carcinoma,adenoid cystic carcinomac.1733G>Ap.R578H25
13COSM143850APCsalivary gland,NS,carcinoma,adenoid cystic carcinomac.4195C>Tp.R1399C25
14COSM3863360SPENsalivary gland,NS,carcinoma,adenoid cystic carcinomac.4207C>Tp.R1403*25
15COSM1659026SLC26A11salivary gland,NS,carcinoma,adenoid cystic carcinomac.1196T>Cp.F399S25
16COSM1658992SLC15A5salivary gland,NS,carcinoma,adenoid cystic carcinomac.925C>Gp.L309V25
17COSM1658863ATP7Bsalivary gland,NS,carcinoma,adenoid cystic carcinomac.2774T>Cp.V925A25
18COSM88749CREBBPsalivary gland,NS,carcinoma,adenoid cystic carcinomac.4336C>Tp.R1446C25
19COSM28795KDM6Asalivary gland,NS,carcinoma,adenoid cystic carcinomac.975-1G>Tp.?25
20COSM496HRASsalivary gland,NS,carcinoma,adenoid cystic carcinomac.181C>Ap.Q61K25
21COSM1658935CHEK2salivary gland,NS,carcinoma,adenoid cystic carcinomac.508G>Ap.V170I25
22COSM1659053TSC1salivary gland,NS,carcinoma,adenoid cystic carcinomac.3280G>Tp.E1094*25
23COSM33972KITsalivary gland,NS,carcinoma,adenoid cystic carcinomac.1915T>Cp.S639P25
24COSM1659099FMNL1salivary gland,NS,carcinoma,adenoid cystic carcinomac.2046G>Ap.K682K25
25COSM1658867NOTCH1salivary gland,NS,carcinoma,adenoid cystic carcinomac.5105T>Cp.F1702S25
26COSM1658926CCDC65salivary gland,NS,carcinoma,adenoid cystic carcinomac.400C>Tp.R134W25
27COSM1659027MRPL24salivary gland,NS,carcinoma,adenoid cystic carcinomac.145A>Gp.I49V25
28COSM1060622ACSL6salivary gland,NS,carcinoma,adenoid cystic carcinomac.911C>Tp.T304M25
29COSM1659005CAMK1Gsalivary gland,NS,carcinoma,adenoid cystic carcinomac.323G>Tp.R108L25
30COSM1659071WASF2salivary gland,NS,carcinoma,adenoid cystic carcinomac.15G>Tp.T5T25
31COSM1658936CACNG3salivary gland,NS,carcinoma,adenoid cystic carcinomac.667C>Tp.R223C25
32COSM1658982TANGO6salivary gland,NS,carcinoma,adenoid cystic carcinomac.352G>Cp.G118R25
33COSM1224460RYR1salivary gland,NS,carcinoma,adenoid cystic carcinomac.5885C>Tp.A1962V25
34COSM1658954SMARCA2salivary gland,NS,carcinoma,adenoid cystic carcinomac.2564G>Ap.R855Q25
35COSM1658921BRD8salivary gland,NS,carcinoma,adenoid cystic carcinomac.2242G>Ap.V748M25
36COSM5010388FGFR2salivary gland,NS,carcinoma,adenoid cystic carcinomac.1922A>Gp.K641R25
37COSM51382KRASsalivary gland,NS,carcinoma,adenoid cystic carcinomac.50G>Ap.S17N25
38COSM1658860CNGA1salivary gland,NS,carcinoma,adenoid cystic carcinomac.1805T>Cp.I602T25
39COSM1659007SMARCA2salivary gland,NS,carcinoma,adenoid cystic carcinomac.3476G>Tp.R1159L25
40COSM1658853ADGRL4salivary gland,NS,carcinoma,adenoid cystic carcinomac.216T>Gp.N72K25
41COSM1658999EDEM2salivary gland,NS,carcinoma,adenoid cystic carcinomac.283C>Ap.Q95K25
42COSM1658995HCRTR2salivary gland,NS,carcinoma,adenoid cystic carcinomac.1166G>Tp.R389L25
43COSM1658899COL22A1salivary gland,NS,carcinoma,adenoid cystic carcinomac.4115G>Cp.G1372A25
44COSM1658915ALOX15salivary gland,NS,carcinoma,adenoid cystic carcinomac.1819G>Ap.G607S25
45COSM34221TIE1salivary gland,NS,carcinoma,adenoid cystic carcinomac.2050G>Cp.A684P25
46COSM1659102LIG1salivary gland,NS,carcinoma,adenoid cystic carcinomac.2382C>Tp.C794C25
47COSM1659070TOMM34salivary gland,NS,carcinoma,adenoid cystic carcinomac.555T>Ap.P185P25
48COSM1659125BIRC6salivary gland,NS,carcinoma,adenoid cystic carcinomac.9339T>Cp.T3113T25
49COSM1658909TFAP2Dsalivary gland,NS,carcinoma,adenoid cystic carcinomac.1306C>Tp.R436W25
50COSM33975KITsalivary gland,NS,carcinoma,adenoid cystic carcinomac.2465A>Gp.N822S25

Copy number variations for Salivary Gland Adenoid Cystic Carcinoma from CNVD:

6 (show top 50)    (show all 209)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1138051161300000DeletionAdenoid cystic carcinoma
23180913120000032688000LossBAI2Adenoid cystic carcinoma
33181013120000032688000LossEIF3S2Adenoid cystic carcinoma
43181113120000032688000LossFABP3Adenoid cystic carcinoma
53181213120000032688000LossHDAC1Adenoid cystic carcinoma
63181313120000032688000LossIQCCAdenoid cystic carcinoma
73181413120000032688000LossKHDRBS1Adenoid cystic carcinoma
83181513120000032688000LossLCKAdenoid cystic carcinoma
93181613120000032688000LossMARCKSL1Adenoid cystic carcinoma
103181713120000032688000LossPTP4A2Adenoid cystic carcinoma
113181813120000032688000LossPUM1Adenoid cystic carcinoma
123181913120000032688000LossRBBP4Adenoid cystic carcinoma
133182013120000032688000LossSERINC2Adenoid cystic carcinoma
143182113120000032688000LossTXLNAAdenoid cystic carcinoma
153392815061800052179000LossCDKN2CAdenoid cystic carcinoma
163392915061800052179000LossEPS15Adenoid cystic carcinoma
173393015061800052179000LossFAF1Adenoid cystic carcinoma
183393115061800052179000LossNRD1Adenoid cystic carcinoma
193393215061800052179000LossRAB3BAdenoid cystic carcinoma
203393315061800052179000LossRNF11Adenoid cystic carcinoma
215014311114500000121200000DeletionAdenoid cystic carcinoma
225014611114500000121200000GainSalivary gland adenoid cystic carcinoma
2358545116840000070400000DeletionAdenoid cystic carcinoma
2458546116840000070400000GainSalivary gland adenoid cystic carcinoma
256197012103800000109000000LOHAdenoid cystic carcinoma
266428312125900000133851895LOHAdenoid cystic carcinoma
27670681235800000133851895LossAdenoid cystic carcinoma
2867236123820000058100000DeletionAdenoid cystic carcinoma
2967639124374300050676000LossACVR1BAdenoid cystic carcinoma
3067640124374300050676000LossACVRL1Adenoid cystic carcinoma
3167641124374300050676000LossADCY6Adenoid cystic carcinoma
3267642124374300050676000LossAMIGO2Adenoid cystic carcinoma
3367643124374300050676000LossANP32DAdenoid cystic carcinoma
3467644124374300050676000LossARF3Adenoid cystic carcinoma
3567645124374300050676000LossATF1Adenoid cystic carcinoma
3667646124374300050676000LossCCNT1Adenoid cystic carcinoma
3767647124374300050676000LossCOL2A1Adenoid cystic carcinoma
3867648124374300050676000LossDDX23Adenoid cystic carcinoma
3967649124374300050676000LossFAIM2Adenoid cystic carcinoma
4067650124374300050676000LossHDAC7AAdenoid cystic carcinoma
4167651124374300050676000LossLALBAAdenoid cystic carcinoma
4267652124374300050676000LossLETMD1Adenoid cystic carcinoma
4367653124374300050676000LossLIMA1Adenoid cystic carcinoma
4467654124374300050676000LossMLL2Adenoid cystic carcinoma
4567655124374300050676000LossPFKMAdenoid cystic carcinoma
4667656124374300050676000LossPLEKHA9Adenoid cystic carcinoma
4767657124374300050676000LossPRKAG1Adenoid cystic carcinoma
4867658124374300050676000LossRACGAP1Adenoid cystic carcinoma
4967659124374300050676000LossRAPGEF3Adenoid cystic carcinoma
5067660124374300050676000LossRHEBL1Adenoid cystic carcinoma

Expression for genes affiliated with Salivary Gland Adenoid Cystic Carcinoma

About this section
Search GEO for disease gene expression data for Salivary Gland Adenoid Cystic Carcinoma.

Pathways for genes affiliated with Salivary Gland Adenoid Cystic Carcinoma

About this section

GO Terms for genes affiliated with Salivary Gland Adenoid Cystic Carcinoma

About this section

Cellular components related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cortical cytoskeletonGO:00308639.9CTTN, NOS2
2cytoplasmGO:00057376.2AQP1, BCL2, CCND1, CDH1, CTTN, KIT

Biological processes related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1developmental pigmentationGO:004806610.6BCL2, KIT
2lymphoid progenitor cell differentiationGO:000232010.5BCL2, KIT
3melanocyte differentiationGO:003031810.5BCL2, KIT
4cellular response to organic substanceGO:007131010.5BCL2, CCND1
5regulation of developmental pigmentationGO:004807010.5BCL2, KIT
6focal adhesion assemblyGO:004804110.3BCL2, CTTN
7hemopoiesisGO:003009710.2BCL2, KIT, RUNX3
8pigmentationGO:004347310.1BCL2, EN1, KIT
9response to iron ionGO:00100399.9BCL2, CCND1
10response to drugGO:00424939.2AQP1, BCL2, CCND1, CDH1

Molecular functions related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1proline-rich region bindingGO:007006410.7CCND1, CYLD
2protein bindingGO:00055155.0AQP1, BCL2, CCND1, CDH1, CTTN, CYLD

Sources for Salivary Gland Adenoid Cystic Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet